Cytotoxicity Analysis of the Effects of Heterobasidion Annosum Mycelia and Cisplatin on Colon Adenocarcinoma (CACO-2) Cell Line
Abstract
Colorectal cancer ranks as the third most prevalent form of cancer and stands as the second leading cause of mortality. Both environmental and genetic risk factors contribute to its manifestation. Presently, 5-fluoruracil/leucovorin (5-FU/LV) remains the recommended course for adjuvant therapy in addressing this condition. Conversely, mushrooms, celebrated for their biologically active constituents, including valuable enzymes, have emerged as a captivating subject in diverse medical disciplines, particularly within the realm of cancer therapy, due to their promising therapeutic properties. This specific investigation aimed to conduct in vitro cytotoxic experiments using extracts obtained from Heterobasidion annosum micelles cultivated in a liquid malt extract medium. The pulverized extracts were dissolved in Dulbecco's Modified Eagle Medium (DMEM) at varied concentrations ranging from 25ng/mL to 200ng/mL and subsequently administered to colon adenocarcinoma (Caco-2) cells. The cytotoxic effects of both the fungus and cisplatin, a well-known anticarcinogenic agent, were examined at intervals of 24, 48, and 72 hours. The findings indicated a significant inhibition of cancer cell development within this timeframe. Moreover, a noteworthy discovery emerged, revealing that cisplatin, known for its efficacy in various cancer studies, substantially diminished the viability of cancer cells after 72 hours in comparison to the control group.
Keywords
Cisplatin, Colon adenocarcinoma, Heterobasidion annosum
Thanks
We would like to thank Isparta University of Applied Sciences Faculty of Forestry faculty member Dr. Lecturer Ayşe Gülden ADAY KAYA for providing the Heterobasidion annosum isolate TR501 used in the study and contributing to our study.
References
- [1] Lotfollahzadeh S., Recio-Boiles A., Cagir B., Colon cancer, Florida: StatPearls Treasure, (2021).
- [2] Alvarez-Gonzalez MA., Pantaleon MA., Flores-Le Roux JA., Zaffalon D., Amorós J., Bessa X., Seoane A., Pedro-Botet J., Randomized Clinical Trial: A Normocaloric Low-Fiber Diet the Day Before Colonoscopy Is the Most Effective Approach to Bowel Preparation in Colorectal Cancer Screening Colonoscopy, Dis Colon Rectum., 62(4) (2019) 491-497.
- [3] Peters WR., What Every Colorectal Surgeon Should Know About the New American Cancer Society's Colorectal Cancer Screening Guidelines, Dis Colon Rectum., 62(4) (2019) 397-398.
- [4] Dasari S., Tchounwou PB., Cisplatin in cancer therapy: molecular mechanisms of action, Eur J Pharmacol., 740 (2014) 364-78.
- [5] Galligioni E., Canobbio L., Figoli F., Fassio T., Frustaci S., Crivellari D., Vaccher E., Lo Re G., Gasparini G., Veronesi A,. Cisplatin and 5-fluorouracil combination chemotherapy in advanced and/or metastatic colorectal carcinoma: a phase II study, Eur J Cancer Clin Oncol., 23(6) (1987) 657-61.
- [6] Gürbüz V., Yilmaz A., Gökçe Ö., Konaç E., İnsan kolon kanser hücre hattında (HT29) sisplatin'in apoptotik etkisi, MarmaraMedJ 24 (2) (2011) 100-105.
- [7] Kaźmierczak-Siedlecka K., Dvořák A., Folwarski M., Daca A., Przewłócka K., Makarewicz W., Fungal Gut Microbiota Dysbiosis and Its Role in Colorectal, Oral, and Pancreatic Carcinogenesis, Cancers (Basel), 12(5) (2020)1326.
- [8] Mann, J., Natural products in cancer chemotherapy: past, present and future, Nat Rev Cancer., 2(2) (2002)143-148.
- [9] Reddy L., Odhav B., Bhoola KD., Natural products for cancer prevention: a global perspective, Pharmacol Ther., 99(1) (2003) 1-13.
- [10] Sande D, Oliveira GP, Moura MAFE, Martins BA, Lima MTNS, Takahashi JA., Edible mushrooms as a ubiquitous source of essential fatty acids, Food Res Int., 125 (2019)108524.